A Phase II Study of Pomalidomide, Daily Low Dose Oral Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma

ID Number 14-0825

Principal Investigator(s)
Ajai Chari

Department(s) or Division(s)
Hematology and Medical Oncology


Multiple Myeloma is a cancer of the blood that is currently incurable- so, even treatments that work may stop working after some time.  The purpose of this study is to determine the safety and activity of a drug known as pomalidomide in combination with two other commercially available drugs i.e., cyclophosphamide and dexamethasone in the treatment of Multiple Myeloma (MM) which has relapsed and is refractory (disease that has come back and did not respond to one or more prior therapies).

Pomalidomide is a third generation immunomodulatory (IMiDs) agent, which is a more potent version of thalidomide and lenalidomide drugs that have been approved by the United States Food and Drug Administration 9FDA) for the treatment of MM.  In February 2013, pomalidomide was also approved by the FDA for patient with MM who have had more than 2 types of therapy.

This study is being done to learn more about the drug and to gather data on its safety and side effects when used in combination with commercially available cyclophophamide and dexamethasone.  This combination is considered experimental and has not been approved by the FDA.  Ask the study doctor if you have any questions about how the study drugs work.

Contact Information
Lisa La
(212) 241-8615

Recruiting Patients: Yes